SNAP-8 (Acetyl Octapeptide-3): Research Guide & Chemical Profile

SNAP-8 (Acetyl Octapeptide-3) is a synthetic peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. The molecular formula is C41H70N16O16S with a molecular weight of approximately 1075.28 Da. The peptide is N-terminally acetylated and C-terminally amidated, modifications that protect against exopeptidase degradation and neutralize terminal charges, improving both stability and membrane interaction potential.

The octapeptide sequence is derived from the N-terminal domain of SNAP-25 (synaptosomal-associated protein of 25 kDa), one of three proteins comprising the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex. SNAP-8 represents an elongated analog of acetyl hexapeptide-3 (Argireline, Ac-EEMQRR-NH2) with two additional C-terminal residues (Ala-Asp) that improve SNARE complex binding affinity and biological potency. The CAS registry number is 868844-74-0.

As a solid, SNAP-8 is a white to off-white hygroscopic powder freely soluble in water and aqueous buffers. The isoelectric point is approximately 5.1 due to the balance of acidic (three Glu/Asp residues) and basic (two Arg residues) side chains. The methionine residue at position 3 represents a potential oxidation-sensitive site, requiring careful handling and storage under inert atmosphere to prevent methionine sulfoxide formation, which reduces biological activity.

• Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2
• Molecular weight: ~1075.28 Da
• Molecular formula: C41H70N16O16S
• CAS number: 868844-74-0
• Parent protein: SNAP-25 N-terminal domain fragment
• Modifications: N-acetyl, C-amide
• Appearance: White hygroscopic powder
• Solubility: Freely soluble in water and aqueous buffers
• pI: ~5.1

The SNARE complex is a molecular machinery essential for membrane fusion events throughout the nervous system, including neurotransmitter release at synaptic junctions. The ternary core SNARE complex consists of three proteins: syntaxin-1 (a t-SNARE anchored in the presynaptic plasma membrane), SNAP-25 (a t-SNARE peripherally associated with the plasma membrane via palmitoylation), and VAMP/synaptobrevin (a v-SNARE anchored in the synaptic vesicle membrane). These three proteins assemble into a highly stable four-helix bundle that drives vesicle-membrane fusion.

SNAP-25 contributes two alpha-helical domains (SN1 and SN2) to the four-helix bundle. The N-terminal domain (SN1, residues 7-82) and the C-terminal domain (SN2, residues 141-203) form parallel coiled-coil structures with syntaxin-1 and VAMP/synaptobrevin. The assembly process begins with the formation of a binary complex between syntaxin-1 and SNAP-25 (the acceptor complex), followed by incorporation of VAMP/synaptobrevin from the vesicle membrane. The progressive zippering of the four-helix bundle from the N-terminal to C-terminal ends generates the mechanical force that pulls the vesicle and plasma membranes together, ultimately driving lipid bilayer fusion and neurotransmitter release.

Botulinum neurotoxins exert their paralytic effects by proteolytically cleaving SNARE proteins. Botulinum toxin type A (BoNT/A) specifically cleaves SNAP-25 between residues Gln197 and Arg198, removing nine C-terminal residues and rendering the truncated protein unable to support efficient SNARE complex assembly and membrane fusion. This established mechanism provides the biological rationale for peptide-based approaches to modulate SNARE function through competitive rather than proteolytic mechanisms.

SNAP-8 is designed to function as a competitive inhibitor of SNARE complex assembly by mimicking a portion of the SNAP-25 N-terminal domain. The octapeptide competes with endogenous SNAP-25 for binding to the syntaxin-1 acceptor site during the initial binary complex formation step. When SNAP-8 occupies the binding site, it cannot support complete four-helix bundle assembly because it lacks the full-length coiled-coil domains required for productive SNARE complex formation. The resulting destabilized or incomplete complexes exhibit reduced efficiency in driving vesicle fusion.

In vitro reconstitution assays using purified recombinant SNARE proteins have demonstrated that SNAP-8 reduces the rate and extent of SNARE-mediated liposome fusion in a concentration-dependent manner. At micromolar concentrations, SNAP-8 inhibited SNARE complex assembly by 30-40% as measured by SDS-resistant complex formation on non-reducing gel electrophoresis. The octapeptide showed approximately 30% greater inhibitory potency compared to the hexapeptide analog (Argireline), attributable to the additional Ala-Asp residues contributing to binding interface stabilization.

The mechanism is fundamentally distinct from botulinum toxin: whereas BoNT/A irreversibly destroys SNAP-25 through enzymatic cleavage, SNAP-8 acts as a reversible competitive inhibitor. This reversibility means that the inhibitory effect is concentration-dependent and dissipates when the peptide is removed or degraded. The kinetics of inhibition follow a competitive model, with the effective inhibition determined by the ratio of SNAP-8 concentration to endogenous SNAP-25 concentration at the presynaptic terminal.

Studies using ex vivo neuromuscular junction preparations have investigated the functional consequences of SNAP-8-mediated SNARE complex modulation. In mouse phrenic nerve-hemidiaphragm preparations, bath application of SNAP-8 at concentrations of 50-200 micromolar produced a concentration-dependent reduction in the amplitude of miniature end-plate potentials (MEPPs) and end-plate potentials (EPPs), consistent with reduced acetylcholine release from presynaptic motor nerve terminals.

Electrophysiological analysis revealed that SNAP-8 reduced the quantal content of neuromuscular transmission (the number of acetylcholine vesicles released per nerve impulse) without affecting the postsynaptic sensitivity to acetylcholine. This selective presynaptic effect is consistent with the proposed mechanism of vesicle fusion inhibition and distinguishes SNAP-8 from postsynaptic neuromuscular blocking agents. The onset of effect was gradual over 30-60 minutes, reflecting the time required for peptide penetration to presynaptic sites.

Importantly, the degree of neuromuscular transmission reduction observed with SNAP-8 is substantially less than that achieved by botulinum toxin. While BoNT/A at picomolar concentrations produces near-complete neuromuscular blockade, SNAP-8 at maximal achievable concentrations reduces transmission by approximately 20-40%. This partial inhibition profile reflects the fundamental limitation of a competitive mechanism versus an enzymatic one: as a reversible competitor, SNAP-8 cannot achieve the sustained, near-complete SNAP-25 inactivation that characterizes botulinum toxin action.

SNAP-8 was developed as an optimized successor to acetyl hexapeptide-3 (Argireline, Ac-EEMQRR-NH2), which was the first commercially available peptide targeting the SNARE complex. Both peptides derive from the SNAP-25 N-terminal domain and share the core hexapeptide sequence, but SNAP-8 includes two additional C-terminal residues (Ala-Asp at positions 7 and 8) that extend the helical binding interface with syntaxin-1.

Comparative in vitro studies demonstrate that SNAP-8 exhibits approximately 30% greater potency than Argireline in SNARE complex assembly inhibition assays and 20-40% greater efficacy in catecholamine release inhibition from chromaffin cells. The enhanced activity is attributed to the additional binding contacts provided by the Ala-Asp extension, which engage residues in the syntaxin-1 binding groove that are not contacted by the shorter hexapeptide. Molecular dynamics simulations support this interpretation, showing a more extensive and stable binding interface for the octapeptide.

From a stability perspective, SNAP-8 and Argireline share similar chemical stability profiles, as both contain the oxidation-sensitive methionine residue and similar terminal modifications. The two additional residues in SNAP-8 modestly increase molecular weight and decrease the lipophilicity index, which may slightly reduce passive membrane permeation compared to the smaller hexapeptide. This trade-off between binding potency and penetration efficiency is a consideration in formulation design.

Chromaffin cell models have been widely used to study SNAP-8 effects on regulated exocytosis. Bovine adrenal chromaffin cells, which release catecholamines (epinephrine and norepinephrine) through SNARE-dependent vesicle fusion, provide a quantifiable model for neurosecretory function. SNAP-8 treatment (50-100 micromolar for 48-72 hours) reduced potassium-stimulated catecholamine release by 25-40% compared to untreated controls, confirming functional inhibition of SNARE-mediated exocytosis.

Primary human keratinocyte cultures have been used to assess cytokine and growth factor secretion modulation by SNAP-8. These cells express SNARE machinery for regulated secretion of inflammatory mediators. SNAP-8 treatment reduced stimulated secretion of IL-6 and IL-8 by approximately 15-25%, suggesting potential modulatory effects on cutaneous inflammatory signaling beyond neuromuscular transmission. However, the physiological significance of this observation requires further investigation.

Three-dimensional skin equivalent models and ex vivo skin organ cultures have been employed to evaluate SNAP-8 effects in a tissue context. In these systems, the challenges of peptide penetration and dilution within tissue compartments significantly reduce effective concentrations at target sites compared to simple cell culture monolayers. Results from tissue models generally show more modest effects than monolayer studies, highlighting the importance of delivery optimization for translational relevance.

As a hydrophilic octapeptide with molecular weight exceeding 1000 Da, SNAP-8 faces significant barriers to passive transdermal penetration. The 500 Dalton rule, an empirical guideline suggesting that molecules above this molecular weight exhibit minimal passive skin penetration, places SNAP-8 well above the conventional permeation threshold. Franz diffusion cell studies consistently show that less than 1% of applied SNAP-8 penetrates beyond the stratum corneum from aqueous solutions within 24 hours.

Chemical penetration enhancement strategies have been explored to improve SNAP-8 bioavailability. Dimethyl sulfoxide (DMSO, 5-10%), oleic acid, and terpene-based enhancers (menthol, limonene) each increased steady-state flux across excised human skin by 2-8 fold. Nanoencapsulation in lipid-based carriers (liposomes, ethosomes, transfersomes) provided 3-6 fold enhancement with improved tolerability compared to chemical enhancers. Chitosan nanoparticles exploiting the cationic polymer interaction with anionic skin surfaces showed particular promise for cationic peptide delivery.

The fundamental bioavailability challenge remains a key consideration in interpreting SNAP-8 research: the concentrations achievable at neuromuscular junctions in intact tissue are orders of magnitude below those used in cell culture studies. This pharmacokinetic limitation underlies the modest in vivo effects compared to in vitro potency and explains the significant gap between the theoretical mechanism (SNARE inhibition) and the magnitude of functional effects observed in tissue-level studies.

Systematic alanine scanning of the SNAP-8 sequence identified Glu1, Glu2, Arg5, and Arg6 as the most critical residues for SNARE complex inhibition. The two glutamic acid residues form salt bridges with basic residues on syntaxin-1, while the arginine pair engages in electrostatic interactions and hydrogen bonding with the syntaxin-1 coiled-coil groove. Substitution of any of these four charged residues with alanine reduced inhibitory activity by 60-80% in SNARE assembly assays.

The methionine at position 3 is moderately important for activity, with alanine substitution reducing potency by approximately 35%. This residue contributes hydrophobic packing interactions within the binding interface. Notably, replacement with norleucine (a non-oxidizable isostere) maintained full activity while eliminating the oxidation liability, representing a potentially improved analog for research applications requiring enhanced stability.

Cyclization strategies, including head-to-tail and side-chain-to-side-chain cyclization, have been explored to improve metabolic stability. Lactam bridge formation between the Glu1 side chain and the Asp8 side chain produced a cyclic analog with 5-fold improved resistance to serum proteases while retaining approximately 70% of the linear peptide inhibitory activity. However, the conformational constraint imposed by cyclization partially disrupts the optimal binding geometry, explaining the modest activity reduction.

Quality control of SNAP-8 follows established analytical peptide chemistry methods. RP-HPLC on C18 columns with TFA/acetonitrile gradient elution provides identity and purity assessment, with typical elution at 25-35% acetonitrile (substantially earlier than lipopeptides due to the hydrophilic nature of the octapeptide). Purity specifications for research-grade material typically require greater than 95% by HPLC area normalization.

Mass spectrometric identity confirmation is performed by ESI-MS with the expected [M+H]+ ion at m/z 1076.28 and [M+2H]2+ at m/z 538.65. LC-MS/MS fragmentation produces a characteristic y-ion series corresponding to sequential C-terminal amino acid losses. The b-ion series beginning with the N-acetyl-glutamic acid residue at m/z 172.06 provides confirmation of the N-terminal acetylation. Amino acid analysis after acid hydrolysis confirms the expected composition, with particular attention to methionine recovery which may be reduced by oxidation during hydrolysis.

Stability-indicating methods must resolve the intact peptide from its primary degradation products: methionine sulfoxide variant (Met(O)-SNAP-8, +16 Da), deamidation products at Gln4 (Glu substitution, +1 Da), and hydrolytic fragments from peptide bond cleavage. Accelerated stability studies at 40°C/75% RH in solution typically show methionine oxidation as the primary degradation pathway, with deamidation as a secondary route. Lyophilized material stored at -20°C under nitrogen shows no significant degradation over 18-24 months.

The following publications represent key research on SNAP-8 (Acetyl Octapeptide-3) and SNARE complex modulation. Researchers are directed to these primary sources for experimental protocols and detailed data.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism